Alumis initiated with a Buy at Stifel

Stifel analyst Alex Thompson initiated coverage of Alumis (ALMS) with a Buy rating and $44 price target The firm, which contends that next-generation TYK2s with the ability to achieve full target coverage have the potential to grow into “an important oral class with the benefit of no Boxed Warning,” says that topline data in psoriasis from Alumis’ envudeucitinib provides support for its positive thesis on the stock.